Senescence-risk signature

1. Senescence-risk signature is associated with tumor immune dysfunction and exclusion in silico.

   “whereas negatively correlated with tumor immune dysfunction and exclusion (TIDE)”

   In silicoprostate cancer patients

   Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer

   Frontiers in immunology·Feb 20, 2023

More on Tumor immune dysfunction and exclusion

1. Senescence-risk signature is associated with tumor mutation burden in silico.

   “the risk score was positively associated with tumor mutation burden (TMB) and immune checkpoint”

   In silicoprostate cancer patients

   Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer

   Frontiers in immunology·Feb 20, 2023

More on Tumor mutation burden

1. Senescence-risk signature predicts prognosis in silico.

   “established a unique prognostic signature in PCa patients based on eight SRGs, including CENPA, ADCK5, FOXM1, TFAP4, MAPK, LGALS3, BAG3, and NOX4, and validated well prognosis-predictive power”

   In silicoprostate cancer patients

   Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer

   Frontiers in immunology·Feb 20, 2023